Benzinga | Jan 20, 2021 06:34AM EST

Cantor Fitzgerald Initiates Coverage On Checkpoint Therapeutics with Overweight Rating, Announces Price Target of $16

Cantor Fitzgerald analyst Jennifer Kim initiates coverage on Checkpoint Therapeutics (NASDAQ:CKPT) with a Overweight rating and announces Price Target of $16.